Clinical Trial Update: Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis [Phase 2]

View source ↗

Summary

Phase 2 study update for tanezumab in moderate to severe pain due to Schwannomatosis; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain
• Schwannomatosis

Drugs mentioned

• Tanezumab (tanezumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Schwannomatosis, Pain | Phase 2 | Status: UNKNOWN